Menu

盐酸纳洛酮属于哪类药?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

What kind of drug does naloxone hydrochloride belong to?

It is a drug that can be used independently without training and is used to reduce deaths caused by opioid overdose. If used promptly, the harm caused by opioid abuse can often be counteracted within minutes. High-dose naloxone offers new options for treating opioid overdose.

About Naloxone Hydrochloride

Naloxone hydrochloride is a specific opioid receptor blocker. It was used clinically in the United States in 1971 and was officially launched in China in 1990. Naloxone hydrochloride is a pure opioid receptor antagonist. It has no intrinsic activity, but it can competitively antagonize various types of opioid receptors. It is widely used in clinical treatment of opioid poisoning, including anesthetic overdose, ethanol poisoning, shock, cerebral infarction, cardiorespiratory arrest and respiratory depression. It has precise curative effect and few side effects.

Naloxone hydrochloride is widely used in acute poisoning caused by overdose of opioid analgesics, and has broad application prospects in the rescue treatment of a variety of critical diseases.

Naloxone Hydrochloride Nasal Spray Launched

Naloxone hydrochloride has serious first-pass hepatic effects and is almost ineffective when taken orally. The FDA approved the marketing of naloxone hydrochloride nasal spray in November 2015. However, there are only two dosage forms in China: injection and sublingual tablets. In April 2021, the U.S. Food and Drug Administration (FDA) announced the approval of a higher-dose naloxone hydrochloride nasal spray product for the treatment of opioid addiction. The newly approved product by the FDA is 8 mg. It has previously approved 2 mg and 4 mg naloxone nasal spray products.

Increasing access to and use of naloxone is part of a targeted strategy unveiled by U.S. Department of Health and Human Services Secretary Burwell in March to address the opioid epidemic and save lives. In July, during an FDA-sponsored workshop exploring the uptake and utilization of naloxone, addiction and advocacy groups called for expanded availability of the drug.

Recommended related articles:

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。